Adalimumab in psoriasis: The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL)
Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18